Entresto

1 articles

Novartis Backs Full-Year Forecast After Profit Beat Driven by One-Offs

Novartis reported a second-quarter profit beat and maintained its 2026 outlook despite facing patent cliffs on key drug Entresto. The company highlighted upcoming trial results for three experimental

reuters · 2026-07-20 22:10

Product Info

Name (EN)	Sacubitril-valsartan
CAS No.	936623-90-4
Molecular Formula	C24H29N5O3.C24H29NO5.<sup>5</sup>/2H2O.3Na
Type	product
Other Names (EN)	L-Valine,N-(1-oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-,compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1′-biphenyl]-4-pentanoate,sodium salt,hydrate (2:2:6:5);LCZ 696;Entresto;Sacubitril-valsartan mixt.;Sacubitril-valsartan;Neparvis